[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE65403T1 - Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit. - Google Patents

Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.

Info

Publication number
ATE65403T1
ATE65403T1 AT87100811T AT87100811T ATE65403T1 AT E65403 T1 ATE65403 T1 AT E65403T1 AT 87100811 T AT87100811 T AT 87100811T AT 87100811 T AT87100811 T AT 87100811T AT E65403 T1 ATE65403 T1 AT E65403T1
Authority
AT
Austria
Prior art keywords
human
promoting
csf
haematopoietic
restoration
Prior art date
Application number
AT87100811T
Other languages
English (en)
Inventor
Masahiko Tamura
Kunihiro Hattori
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11745897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE65403(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE65403T1 publication Critical patent/ATE65403T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT87100811T 1986-01-22 1987-01-21 Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit. ATE65403T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1028086 1986-01-22
EP87100811A EP0230980B2 (de) 1986-01-22 1987-01-21 Pharmazeutischer Stoff für die Förderung der Wiederherstellung der hämatopoietischen Fähigkeit

Publications (1)

Publication Number Publication Date
ATE65403T1 true ATE65403T1 (de) 1991-08-15

Family

ID=11745897

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87100811T ATE65403T1 (de) 1986-01-22 1987-01-21 Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.

Country Status (5)

Country Link
EP (1) EP0230980B2 (de)
AT (1) ATE65403T1 (de)
CA (1) CA1297004C (de)
DE (1) DE3771509D1 (de)
ES (1) ES2039209T5 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
WO1992011022A1 (en) * 1990-12-25 1992-07-09 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical preparation for pernasal administration
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
EP0953354A4 (de) 1996-08-13 2002-10-23 Fujisawa Pharmaceutical Co Hämatopoietische stammzellen proliferierende wirkstoffe
DE19860801A1 (de) * 1998-12-30 2000-07-06 Rhein Biotech Proz & Prod Gmbh Rekombinanter Wachstumsfaktor mit der biologischen Aktivität eines G-CSF (Granulocyte Colony Stimulating Factor)
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
WO2003006501A2 (en) 2001-07-11 2003-01-23 Maxygen Holdings, Ltd. G-csf conjugates
EP1463751B1 (de) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albuminfusionsproteine
CA2537158C (en) 2002-08-27 2014-07-22 Hirokazu Tamamura Cxcr4 antagonist and use thereof
DE602006020562D1 (de) 2005-06-01 2011-04-21 Maxygen Inc Hren dafür
US8663651B2 (en) 2006-12-21 2014-03-04 Biokine Therapeutics Ltd. T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
CA2765345C (en) 2009-06-14 2016-06-21 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
EP2841084B1 (de) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptid zur verwendung in der behandlung von lungenkrebs
DE102014001250C5 (de) 2014-02-03 2021-07-29 Carl Freudenberg Kg Fensterwischer
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
BR112018016924A2 (pt) 2016-02-23 2019-01-02 Biokine Therapeutics Ltd método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
EP0215126B1 (de) * 1985-02-08 1991-07-31 Chugai Seiyaku Kabushiki Kaisha Menschlicher granuloxcyt-kolonie-stimulierungsfaktor

Also Published As

Publication number Publication date
CA1297004C (en) 1992-03-10
DE3771509D1 (de) 1991-08-29
EP0230980B1 (de) 1991-07-24
EP0230980B2 (de) 1996-03-20
EP0230980A3 (en) 1988-07-27
ES2039209T5 (es) 1996-07-16
ES2039209T3 (es) 1993-09-16
EP0230980A2 (de) 1987-08-05

Similar Documents

Publication Publication Date Title
ATE65403T1 (de) Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
DE3683430D1 (de) Einen menschlichen granulozytkoloniereizfaktor fuer die behandlung von leukopenien enthaltende pharmazeutische zubereitung.
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
ATE227587T1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
IL78553A (en) Therapeutic compositions of phosphonylmethoxyalkyl adenines
EP0177910A3 (de) Verwendung von Interferon-gamma (IFN-gamma) enthaltenden Präparationen zur systemischen Behandlung von verschiedenen Erkrankungen des Menschen in niedriger Dosierung
MX9603927A (es) Metodo para la estimulacion de hematopoyesis con hemoglobina.
CA2068324A1 (en) Metal-peptide compositions and methods for stimulating hair growth
EP0151989A3 (en) Means for the treatment of cardiac diseases
ATE74272T1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
WO1989000582A3 (en) Human granulocyte-macrophage colony stimulating factor and muteins thereof
NZ224116A (en) Compositions of interleukin-2 and fk565; method of stimulation of the immune system and package
DE3771584D1 (de) Zusammensetzungen und anwendung von interleukin-2 und/oder interferon-beta und des tumor-necrosis-faktors fuer eine kombinationstherapie oder zur herstellung von arzneimitteln oder formulierungen.
DE3689921D1 (de) Menschlicher plazentarer angiogenischer Faktor, geeignet für die Reizung der Kapillarsynthese, der Endothelzellprotease, der DNS-Synthese und der Absiedlung.
IT8767494A0 (it) Composizione liquida per il trattamento preventivo e curativo di malattie crittogamiche di tipo oidio e procedimento per la messa in opera di tale composizione
EP0158880A3 (en) Liposomes with inhalable allergens for treatment of allergies, method for their preparation and pharmaceutical compositions containing them
ATA269387A (de) Pharmazeutisches mittel zur förderung und stimulierung des haarwachstums und zur verringerung von haarausfall auf basis von pyrimidinderivaten, sowie verwendung des mittels
SI1016414T1 (en) Human growth hormone to stimulate hematopoiesis and immune reconstitution after hematopoietic stem cell transplantation in humans
DE69330809D1 (de) Therapeutisches Agens für Neutropenie
Seki et al. Induction of eosinophil chemotactic factor production from human peripheral blood mononuclear cells by solubilized BALL-1, a B cell lymphoma line

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time